Key Approval

The Board considered and approved the Standalone Unaudited Financial Results of the company for the quarter ended 30th June, 2026 along with the Limited Review Report thereon.

Financial Results Overview

Revenue Performance:

  • Revenue from operations: ₹3,691.39 lakh for Q1 FY27 (compared to ₹2,235.12 lakh in Q1 FY26 and ₹2,519.36 lakh in Q4 FY26)
  • Other income: ₹0.12 lakh for Q1 FY27
  • Total revenue: ₹3,691.51 lakh for Q1 FY27, representing significant growth year-over-year

Expense Breakdown:

  • Purchases of stock-in-trade: ₹3,193.39 lakh
  • Change in inventories: ₹292.95 lakh (increase)
  • Employees benefits expenses: ₹19.66 lakh
  • Finance cost: ₹11.54 lakh
  • Depreciation amortization expenses: ₹7.00 lakh
  • Other expenses: ₹55.44 lakh
  • Total expenses: ₹3,579.98 lakh

Profitability Metrics:

  • Profit from ordinary activities before tax: ₹111.53 lakh
  • Tax expenses: ₹25.64 lakh (current tax) and deferred tax impact
  • Profit for the period: ₹117.89 lakh after accounting for tax and other items

Earnings Per Share:

  • Basic EPS: ₹0.49 (not annualized)
  • Diluted EPS: ₹0.49 (not annualized)

Comparative Performance

Quarter-over-Quarter Comparison (Q1 FY27 vs Q4 FY26):

  • Revenue increased from ₹2,519.36 lakh to ₹3,691.51 lakh
  • Profit before tax decreased from ₹123.29 lakh to ₹111.53 lakh

Year-over-Year Comparison (Q1 FY27 vs Q1 FY26):

  • Revenue increased from ₹2,235.12 lakh to ₹3,691.51 lakh
  • Profit before tax increased significantly from ₹16.94 lakh to ₹111.53 lakh

Business Segment Information

The company has only one business segment: 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)'.

Share Capital Information

  • Face value of shares: ₹10 each
  • Number of shares: 2,389.50 lakh (current) vs 2,108.50 lakh (previous periods)

Company Name Change Context

The company was formerly known as Trimurthi Limited and changed its name due to change in business activity. The company is required to include turnover from new activities separately for 3 years from the date of name change, but as the company carries only one activity currently, separate disclosure is not provided.

Additional Information

  • The results are available on the company's website (www.novelixpharma.com) and BSE website
  • The company has no subsidiary, associate or joint venture companies as of June 30, 2026
  • The limited review report was issued by CVS Balachandra Rao & Co., Chartered Accountants with membership number 204580